Developing countries face a seemingly insurmountable hurdle in providing healthcare to their rapidly growing — or, in some cases, rapidly aging — populations, especially as health systems become increasingly over-burdened and infections and other diseases spread. Because access to medicine in these regions is a multifaceted challenge, it is best tackled by several parties.
Lasting, collaborative relationships among pharmaceutical companies, governments, nonprofit organizations and community leaders are needed to help disadvantaged populations overcome their healthcare challenges. Together, these parties should take a binary approach, addressing both “hardware” factors (which remain constant, such as physical distance to treatment centers and elongated supply chains) and “software” factors (the intangibles that vary greatly in each region, such as the role of family and cultural beliefs).
These principles are especially true in places like China’s rural Xinjiang Uighur Autonomous Region, where life expectancy is stunted at 67 years (compared with 73.5 for China as a whole), and lack of access to healthcare undermines well-being. Xinjiang covers nearly 1.7 million square kilometers, but it is home to only 21 million people, many of whom are members of nomadic tribes. From an economic standpoint, Xinjiang’s resilience is crucial to China’s economic growth strategy — it is seen as the country’s gateway to the West.
However, the reality is that maintaining the livelihood and well-being of this area’s population and those in other rural parts of China is a serious challenge. Throughout rural China, the spread of infectious diseases — particularly hepatitis B, which affects millions — reflects a lack of hygiene education. The Chinese Ministry of Health cited a 9.5 percent increase in deaths caused by infectious diseases from 2011 to last year. Moreover, there is a serious shortage of healthcare workers — just 1.3 per 1,000 rural inhabitants in China.
Free medicines are only part of the solution. We need to go beyond donations and reduced-pricing schemes to build sustainable healthcare systems with strong distribution channels and education programs for the public and for healthcare workers. Without these components, the model collapses.
Through public-private partnerships, we can leverage unique strengths and be better equipped to expand access to healthcare. This can create a symbiotic relationship, offering benefits to government, business and the local community.
For example, Novartis’ Jian Kang Kuai Che (“Health Express”) program in Xinjiang is a partnership between Novartis and the local government that aims to expand access to medicine, build capacity and educate the public. Health Express achieves this by training local physicians in prevention and treatment of infectious diseases and educating primary and middle-school students on health and hygiene via a traveling caravan that moves from school to school.
During a recent trip to Xinjiang, I met several physicians from rural hospitals who had received training through Health Express. They told me that in the past, hepatitis patients had to travel for hours to be diagnosed and treated at a city hospital, while many others who were unable to make the journey suffered without treatment. Now, with physicians trained in infectious diseases, hepatitis treatment is possible in rural areas of Xinjiang, and patient outcomes have improved significantly.